Revvity Ro 15-1788, -, 250µci (9.25mbq)

Revvity 250µCi quantities of Ro 15-1788, [N-Methyl-³H]-, are available for research. Ro 15-1788 acts as a selective benzodiazepine antagonist. It is used to treat benzodiazepine overdoses and reverse anesthesia. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET757: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Benke D, Cicin-Sain A, Mertens S, Mohler H. Immunochemical identification of the alpha 1- and alpha 3-subunits of the GABAA-receptor in rat brain. J Recept Res. 1991;11(1-4):407-24.Goeders, N., Kuhar, M.J. Benzodiazepine receptor binding invivo with [3H]-Ro 15-1788, Life Sciences, Volume 37, Issue 4, 1985, Pages 345-355.